Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

T-cell-based therapies have emerged as one of the most clinically effective ways to target solid and non-solid tumors. HER2 is responsible for the oncogenesis and treatment resistance of several human solid tumors. As a member of the HER family of tyrosine kinase receptors, its over-activity confers...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Albaitero, Andres, Xu, Hong, Guo, Hongfen, Wang, Linlin, Wu, Zhihao, Tran, Hoa, Chandarlapaty, Sarat, Scaltriti, Maurizio, Janjigian, Yelena, de Stanchina, Elisa, Cheung, Nai-Kong V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384386/
https://www.ncbi.nlm.nih.gov/pubmed/28405494
http://dx.doi.org/10.1080/2162402X.2016.1267891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384386/
https://www.ncbi.nlm.nih.gov/pubmed/28405494
http://dx.doi.org/10.1080/2162402X.2016.1267891

Ejemplares similares